Welcome to our dedicated page for ROCKWELL MEDICAL SEC filings (Ticker: RMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ROCKWELL MEDICAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ROCKWELL MEDICAL's regulatory disclosures and financial reporting.
ROCKWELL MEDICAL, INC. senior vice president and chief commercial officer Timothy Chole reported a routine tax-related share disposition. On the vesting of restricted stock units, 2,444 shares of common stock were withheld at $0.90 per share to cover estimated tax obligations. Following this withholding, he directly holds 122,855 shares of Rockwell Medical common stock.
ROCKWELL MEDICAL, INC. reported a routine tax-related share disposition by its President and CEO, Mark Strobeck. On the reported date, 7,333 shares of common stock were withheld in connection with the vesting of restricted stock units to cover estimated tax obligations, rather than being sold on the open market. Following this withholding, Strobeck directly owns 323,493 shares of Rockwell Medical common stock.
Rockwell Medical, Inc. submitted a current report describing that it has issued a press release with preliminary, unaudited financial results for the quarter and full year ended December 31, 2025. These figures are based on management’s initial analysis and remain subject to the company’s normal quarter-end and year-end closing procedures, internal review, and audit by its independent registered public accounting firm, so actual results may differ from the preliminary figures in the press release.
The report clarifies that the information under the results section and the attached press release are being furnished, not filed, which affects how they are treated under securities laws. It also highlights that the press release includes forward-looking statements about future financial condition, operating results, revenue growth, profitability, cost reductions, and product diversification, all of which are subject to risks described in Rockwell Medical’s prior SEC filings.
Rockwell Medical director reports new equity awards
A director of Rockwell Medical, Inc. (RMTI) reported receiving equity compensation on November 17, 2025. The filing shows an award of 25,000 shares of common stock, described as restricted stock units that vest on November 17, 2026, subject to continued service. After this grant, the director beneficially owns 25,000 common shares directly.
The director was also granted stock options for 25,000 shares of common stock at an exercise price of $0.87 per share, expiring on November 17, 2035. These options vest on November 17, 2026, also conditioned on continued service. The Form 4 notes that it is being filed late due to administrative delays in obtaining the director’s EDGAR codes.
Rockwell Medical, Inc. (RMTI) director files initial ownership report with no holdings
A reporting person serving as a director of Rockwell Medical, Inc. has filed a Form 3, which is the initial statement of beneficial ownership of securities. The filing states that no securities are beneficially owned by the reporting person at this time. The form is filed on an individual basis for one reporting person.
The filing also notes that it was submitted late because of administrative delays in obtaining the reporting person’s EDGAR access codes. A power of attorney is referenced, authorizing an attorney-in-fact to sign the form on the reporting person’s behalf.
Rockwell Medical, Inc. (RMTI) director John G. Cooper reported an open-market sale of company stock. On November 18, 2025, he sold 5,079 shares of Rockwell Medical common stock at a price of $0.87 per share, according to this Form 4 filing. After this transaction, Cooper beneficially owns 140,372 shares of Rockwell Medical common stock, held directly.
Rockwell Medical, Inc. reported a change in its Board of Directors. On November 17, 2025, Andrea Heslin Smiley resigned from the Board and its committees, and the company stated that her resignation was not due to any disagreement over operations, policies, or practices.
The Board appointed Joseph H. Dawson, aged 60, as a Class II director effective the same day, to serve until the 2026 Annual Meeting of Stockholders. He will also serve on the Nominating and Corporate Governance Committee.
Under the non-employee director compensation policy, Mr. Dawson will receive an annual cash retainer of $45,000 as a director and $5,000 for serving on the committee, pro-rated through the 2026 Annual Meeting. He was granted an option to purchase 25,000 shares of common stock and 25,000 restricted stock units under the Amended and Restated 2018 Long Term Incentive Plan, with both equity awards vesting on November 17, 2026, subject to continued service.
Rockwell Medical, Inc. (RMTI) furnished an updated corporate presentation under Regulation FD. The presentation, dated November 12, 2025, is provided as Exhibit 99.1 to a Form 8‑K.
The company states the information in this report, including Exhibit 99.1, is furnished and not deemed “filed” under the Exchange Act pursuant to General Instruction B.2. The exhibit list also includes Exhibit 104 for the cover page interactive data file.
Rockwell Medical (RMTI) reported a weaker quarter. Q3 2025 net sales were $15.9 million versus $28.3 million a year ago, driving gross profit of $2.3 million and an operating loss of $1.6 million. Net loss was $1.8 million, or $0.05 per share, compared with net income of $1.7 million last year.
For the first nine months, net sales were $50.9 million versus $76.8 million, with a net loss of $4.8 million. Cash, cash equivalents and available-for-sale investments totaled $23.7 million, and net working capital was $27.9 million; management believes funds are sufficient for at least the next twelve months.
DaVita extended its purchase agreement through December 31, 2025 but is transitioning to another supplier. Rockwell recognized non-refundable payments of $1.7 million year-to-date, including $0.4 million in Q3, and continues to supply DaVita. The company raised $8.0 million gross ($7.8 million net) via its ATM in Q3, with $13.1 million remaining available. Rockwell closed its Greer, South Carolina facility, recording $0.5 million in Q3 and $0.8 million year-to-date in closure costs. Term loan balance was $8.7 million, interest-only through 36 months, with all covenants in compliance. Shares outstanding were 39,405,301 as of September 30, 2025.
Rockwell Medical, Inc. (RMTI) furnished its quarterly results press release. The company reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and furnished it as Exhibit 99.1 to a Form 8-K.
Consistent with General Instruction B.2, the Item 2.02 information and Exhibit 99.1 are furnished, not filed, and are not incorporated by reference into other filings unless expressly stated. The report was signed by Chief Executive Officer Mark Strobeck.